Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Gold ETF That Makes a Difference

The U.S. Global GO GOLD and Precious Metal Miners ETF (NYSE: GOAU) just had its two-year anniversary at the end of June, and since inception, the fund has absolutely obliterated its main competition. GOAU delivered a remarkable 41% since inception through July 24, cru...

Top Gold Stocks – January 2020

Gold is the most popular precious metal to invest in. Gold is what’s known as a “safe haven asset” where investors buy-in as a way of diversifying risk, especially through futures contracts and derivatives. Like other markets, gold is subj...

U.S. Biotech Makes 'The Acquisition We Were Waiting For'

By tucking in this retinal gene therapy firm, the Massachusetts-based company gains assets and synergy. In a March 4 BTIG research note, analyst Thomas Shrader reported that Biogen Inc. (BIIB:NASDAQ) entered into an agreement to acquire Nightstar Therapeutics Pl...

Oncology Vaccine Developer's Lead Programs 'On Track or Better'

The biopharma's two assets are discussed and Q1/19 financial results are provided in a BTIG research report. In a May 13 research note, BTIG analyst Thomas Shrader reported that Gritstone Oncology Inc.'s (GRTS:NASDAQ) lead clinical programs, GRANITE and SL...

Biopharma Buys 'Insurance Policy Ahead of First Commercial Launch'

The terms of the financial transaction and the potential reasons for it are discussed in a BTIG report. In a June 26 research note, BTIG analyst Thomas Shrader reported that Esperion Therapeutics Inc. (ESPR:NASDAQ) agreed to an "up to $200 capped, tier...

Topline Results from Lipid-Lowering Trial 'Just What the Doctor Ordered'

The study data and their implications are provided in a BTIG report. In an Aug. 29 research note, BTIG analyst Thomas Shrader reported that just released topline data are "as hoped" from Esperion Therapeutics Inc.'s (ESPR:NASDAQ) Phase 2 trial of bempedoic acid-ezet...

Antibody Developer Taken Out by Gilead at 'Hefty Premium'

The reasons Forty Seven attracted a buyer and its near-term catalysts are provided in a BTIG report. In a March 2 research note, BTIG analyst Robert Hazlett reported that Forty Seven Inc. (FTSV:NASDAQ) is being acquired by Gilead Sciences Inc. (GILD:NASDA...

ROCK ready to roll in Saskatchewan

Drills are turning at the Knife Lake Project in Saskatchewan, where Rockridge Resources (TSX-V:ROCK) hopes to meld a resource estimate onto the advanced exploration project rich in volcanogenic massive sulfides (VMS). Knife Lake is currently owned by Eagle Plains Resources...

Geophysical work begins at Finland palladium play

Palladium has found another gear as it races past $2,200 an ounce, leaving its sister platinum-group metal platinum, and even gold, eating its dust. On Tuesday palladium (Pd) hit a record $2,191 an ounce, building on nine straight sessions of gains, but even that wasn&Clo...

Profiting from Europe's new gold rush

Europe owns a sizable chunk of the world's natural resources. Over the past few decades, however, EU countries have mostly imported their resources. Outlandish? Maybe. But it was simply easier, cheaper, and most importantly it avoided most environmental conflicts. Ge...
1 2 3 4 5 6 7 8 9 10 ...